Navigating the Clinical Trial Process for Hepatocellular Carcinoma

A Critical Analysis of Hepatocellular Carcinoma Trials: Perspectives From Patient Experiences

Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.

The goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation.

Insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.

Inclusion Criteria:

• Diagnosed with hepatocellular carcinoma
• Willing to comply with all study related procedures and assessments
• Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol

Exclusion Criteria:

• No documented diagnosis of hepatocellular carcinoma
• Any serious and/or unstable pre-existing medical disorders
• Pregnant or lactating woman